COVID-19 vaccine uptake in patients with cancer and Sars-Cov-2 infection in 2020: Results from the ASCO registry.

Authors

null

Jen Hanley Hanley Williams

American Society of Clinical Oncology, Alexandria, VA

Jen Hanley Hanley Williams , Suanna Steeby Bruinooge , Melinda Kaltenbaugh , Julie R. Gralow , Elizabeth Garrett-Mayer

Organizations

American Society of Clinical Oncology, Alexandria, VA, Seattle Cancer Care Alliance, Seattle, WA

Research Funding

Conquer Cancer Foundation of the American Society of Clinical Oncology

Background: The availability of safe and effective COVID-19 vaccines has enabled protections against serious outcomes from SARS-CoV-2 infection. The ASCO Registry provides an opportunity to study the rate of vaccine uptake among patients (pts) with cancer who had SARS-CoV-2 infection prior to availability of vaccines. Methods: Participating US medical oncology practices identify pts eligible for inclusion: pts with a positive SARS-CoV-2 test and, at the same time, either (a) or (b) cancer-free less than 12 months (i.e., in complete remission or post-resection) and receiving adjuvant treatment. Registry data were extracted on 2/4/22. Pts in this analysis had a SARS-CoV-2 positive test between 3/1/2020 and 12/31/2020 and at least one clinical encounter on or after 1/1/21, documenting receipt or not of 1st and 2nd vaccine shots. Pts lacking data on vaccination status in their medical records were excluded from analysis. When the exact date of 1st vaccine shot was known, the primary endpoint was number of days from 1/1/21 to 1st shot date. If the exact date of 1st shot was unknown, date was categorized as within 7 days from the clinical encounter, 2-4 weeks, or more than 1 month prior. Summary statistics and 95% confidence intervals (CIs) were calculated using Kaplan-Meier methods. Results: The Registry included 1260 pts with SARS-CoV-2 infection in 2020. Time to vaccination (described using cumulative incidence) across age categories is shown in Table, with 1/1/21 as the baseline. Median time to vaccination ranged from 63 days in the oldest pts (> 80 years of age) to 220 days in the youngest pts (< 45 years of age). Differences in rates of vaccination uptake were most pronounced in the early months (Jan – Mar) and diminished in April and beyond. Conclusions: Older pts with cancer who were infected with SARS-CoV-2 in 2020 received COVID-19 vaccinations in 2021 at higher rates than those of younger ages. Delayed uptake by younger aged pts at outset could be related to lack of clarity on pts with cancer qualifying for early vaccine access and state policies on availability.

Age (years)
n
Median number of days to 1st vaccine shot from 1/1/21

(date)1
% 1st vax by 4/1/21

(95% CI)
% 1st vax by 7/1/21

(95% CI)
% 1st vax by 10/1/21

(95% CI)
% 1st vax by 1/1/22

(95% CI)
< 45
124
220

(8/8/21)
27%

(18%, 36%)
45%

(33%, 55%)
60%

(46%, 70%)
72%

(52%, 83%)
45-64
529
115

(4/23/21)
39%

(34%, 43%)
58%

(53%. 63%)
71%

(65%, 75%)
78%

(72%, 82%)
65-80
519
81

(3/22/21)
54%

(49%, 59%)
68%

(63%, 72%)
77%

(72%, 81%)
87%

(81%, 91%)
> 80
88
63

(3/4/21)
69%

(57%, 78%)
81%

(69%, 88%)
90%

(78%, 95%)
95%

(82%, 98%)

1 Estimated date at which 50% of the pts had received 1st vaccination Vax = vaccination

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e18713)

DOI

10.1200/JCO.2022.40.16_suppl.e18713

Abstract #

e18713

Abstract Disclosures

Funded by Conquer Cancer

Similar Abstracts

Abstract

2023 ASCO Quality Care Symposium

Improving bivalent COVID-19 vaccination rates among adult patients with cancer: An ASCO/CDC initiative.

First Author: Michael Jisoo Lee

Abstract

2022 ASCO Annual Meeting

Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.

First Author: Suanna Steeby Bruinooge

First Author: Mengni Guo